AMZN
Amazon.com, Inc.
AMZN's fundamentals are mixed: revenue grew 15%, but free cash flow turned negative. Its PE of 22x looks cheaper than it really is, because one-off gains boosted its recent earnings. Analysts expect strong earnings growth.
NOMA
Nomadar Corp.
There isn't enough reported data to score NOMA yet.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
NOMA Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Unavailable | |
| Unavailable |
NOMA's revenue is currently strong, but its profitability is weak. There isn't enough data to rate its cash flow and balance sheet.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN's PE is in its cheap range at 22x, but its recent earnings include one-off gains. On analysts' estimates for next year's earnings, today's price would be 27x.
NOMA PE Valuation
NOMA has no meaningful PE right now: it lost money over the past year.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
NOMA Forward outlook
There aren't enough analyst estimates for NOMA to show an outlook.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN's earnings per share have climbed steadily: $12.37 over the past year, up 75% from the year before, and higher year over year for 14 quarters in a row. Its recent earnings include one-off gains.
NOMA Earnings Per Share
NOMA and AMZN do not have enough comparable growth data to identify a winner.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN's revenue has grown year over year every quarter since late 2020: $202B last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN has the edge over NOMA on profitability, with a higher operating margin.
NOMA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $669.6K | +114% |
| Q1 2026 | $403.8K | +116% |
| Q4 2025 | $44.3K | +452% |
NOMA's revenue has grown year over year every quarter since late 2025: $669,571 last quarter, up 114% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -33% | +40 points |
| Q1 2026 | -193% | -40 points |
| Q4 2025 | -4256% | +1771 points |
| Q3 2025 | -77% | N/A |
| Q2 2025 | -73% | N/A |
| Q1 2025 | -153% | N/A |
| Q4 2024 | -6027% | N/A |
NOMA's operating margin was −33% last quarter, up 40 points from the same quarter a year ago.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
NOMA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$577.1K | -9050% |
| Q1 2026 | -$183.6K | -485% |
| Q4 2025 | $563.6K | +$878K |
NOMA and AMZN do not have enough comparable growth data to identify a winner.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has the edge over NOMA on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
NOMA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +14% | +2.1M shares |
| 1 year | +7.6% | +1.2M shares |
NOMA has 17M diluted shares, up 7.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NOMA Net Leverage
NOMA's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
NOMA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 15.0 | Oversold |
| Stochastic | 4.0 | Oversold |
NOMA's weekly RSI is 15 (oversold) and its Stochastic is 4 (oversold).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
NOMA PE vs Consumer Cyclical Sector
NOMA has no meaningful PE right now: it lost money over the past year.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN has stronger trend alignment. AMZN is above 5 of 5 weekly averages versus NOMA above 0 of 3.
NOMA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.48 | 39% below |
| 20 week MA | $2.17 | 58% below |
| 50 week MA | $3.50 | 74% below |
NOMA is in a downtrend: it's below all three of its weekly moving averages, and 74% below its 50-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over NOMA on returns for 2026, with the stronger performance.
NOMA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $21.0 | $5.47 | -74% |
| 2026 YTD | $5.47 | $0.91 | -83% |
NOMA has finished every year since 2025 lower, and it's down 83% so far in 2026.